I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $332.33M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
| ||||
454 Life Sciences |
Branford, Conn. |
9/18 |
$20 |
454 Life Sciences raised $20M in an equity financing with investors CuraGen Corp., members of its management team, as well as Cooper Hill and Quantum Partners |
|
||||
Adenosine Therapeutics LLC |
Charlottesville, Va. |
9/9 |
ND |
Adenosine completed a round of venture financing with Emerging Technology Partners |
|
||||
Ambrx Inc. |
San Diego |
9/22 |
$12.5 |
Ambrx raised $12.5M in a Series A round; investors were 5AM Ventures and Tavistock Life Sciences |
|
||||
AmpliMed Corp. |
Tucson, Ariz. |
9/16 |
$5 |
AmpliMed raised $5M in a private financing led by Valley Ventures III LP; other investors were Biotech Insight Management, Invest Bio, Solstice Capital and others |
|
||||
Conforma Therapeutics Corp. |
San Diego |
9/18 |
$30 |
Conforma raised $30M in a private placement of Series C stock; the financing was led by S.R. One Ltd.; other investors were Lilly BioVentures, Novo A/S, RBC Capital Partners, RiverVest Venture Partners, Domain Associates, ProQuest Investments, Forward Ventures and Inglewood Ventures |
|
||||
FivePrime Therapeutics Inc. |
South San Francisco |
9/25 |
$12 |
FivePrime raised $12M in a second round co-led by Kleiner Perkins Caufield and Byers, Versant Ventures and TPG Ventures; new investors were Advanced technology Ventures, Singapore Economic Development Board and The Wellcome Trust |
|
||||
Genstruct Inc. |
Cambridge, Mass. |
9/8 |
$6.5 |
Genstruct raised $6.5M in a Series A round coled by A.M. Pappas and Associates and Flagship Ventures |
Neuro3d |
Paris |
9/10** |
€10 (US$11.25) |
Neuro3d raised US$11.25M in a third funding round; investors were Sofinnova Partners, Apax Partners, HealthCap and Techno Venture Management |
|
||||
NeuroNova AB |
Stockholm, Sweden |
9/10 |
SEK109.5 (US$13.4) |
NeuroNova raised US$13.4M after completing a round of financing with investors HealthCap, Investor Growth Capital and Scandinavian Life Science Venture |
|
||||
OncoGenex Technologies Inc. |
Vancouver, British Columbia |
9/29 |
$11.5 |
OncoGenex raised $11.5M in a private financing led by Ventures West; other investors were H.I.G. Ventures, Working Opportunity Fund, Business Development Bank of Canada and Milestone Medica Corp. |
|
||||
ParAllele BioScience Inc. |
South San Francisco |
9/23 |
$22.5 |
ParAllele raised $22.5M in a Series B financing led by Mohr Davidow Ventures; other investors were Abingworth Management, Index Ventures and Versant Ventures |
|
||||
Psychiatric Genomics Inc. |
Gaithersburg, Md. |
9/10 |
$6 |
Psychiatric Genomics raised $6M in a financing commitment with the Stanley Medical Research Institute |
|
||||
Reliant Pharmaceuticals LLC |
Liberty Corner, N.J. |
9/30 |
$115 |
Reliant raised $115M in an initial Series D closing; the financing was led by Invemed Catalyst Fund LP, and included investments by Bay City Capital Fund III LP, business interests of the Pritzker family, BayStar Capital and the family interests of Ernest Mario, Reliant's chairman and CEO |
|
||||
Targeted Molecules Corp. |
San Diego |
9/11 |
$0.5 |
Targeted Molecules raised $4M total in a financing begun in August; $3.5M of the financing was accounted for in the August chart |
|
||||
TGN Biotech Inc. |
St-Tite-des-Caps, Quebec |
9/4 |
C$5 (US$3.6) |
TGN Biotech raised US$3.6M in a second round |
|
||||
Therion Biologics Corp. |
Cambridge, Mass. |
9/9 |
$39 |
Therion raised $39M; investors were HansWerner Hector, Hambrecht and Quist Capital Management LLC and S.R. One Ltd. |
|
||||
U3 Pharma AG |
Martinsried, Germany |
9/15 |
€13.25 (US$14.88) |
U3 Pharma closed a US$14.88M second round co-led by Atlas Venture and LCF Rothschild Venture Partners; other investors were Biomedi- cal Sciences Investment Fund, Alta Partners, BioM and Medicis Venture Management |
|
||||
Xention Discovery Ltd. |
Cambridge, UK |
9/17** |
£4 (US$6.4) |
Xention raised US$6.4M in its second-round; investors were BTG International Ltd., Quester, Albany Ventures, and Enterprise Venture Capital Trust plc, as well as MVM Ltd. and Isis Equity Partners plc |
|
||||
ZGene A/S |
Ballerup, Denmark |
9/10** |
DKK15 (US$2.3) |
ZGene raised US$2.3M in a second funding round; investors were Symbion Capital I A/S and Dansk Innovationsinvestering P/S |
|
||||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $0.5M | ||||
Company (Symbol)#* |
Partner (Country) |
Amt. (M) |
Triggering Event |
Details (Date) |
| ||||
Affinium Pharmaceuticals Inc.* (Canada) |
Pfizer Inc. |
ND |
Milestone payments |
Affinium received discovery milestone payments after achieving goals for production, functional characterization and structure determination of targets in its collaboration with Pfizer (9/25) |
|
||||
Applied Molecular Evolution Inc. (AMEV) |
MedImmune Inc. (MEDI) |
ND |
Milestone payments |
Applied Molecular received the payments as a result of the initiation of Phase II trials for Vitaxin in cancer and rheumatoid arthritis (9/10) |
|
||||
BioFocus plc (UK; LSE:BIO) |
Axxima Pharmaceuticals AG (Germany) |
ND |
Milestone payment |
BioFocus will receive the payment after identifying lead compounds active against a kinase target (9/9) |
|
||||
DeCode Genetics Inc. (Iceland; DCGN) |
Merck & Co. Inc. |
ND |
Milestone payment |
DeCode received a milestone payment after identifying a gene that in one form predisposes to obesity and in another form predisposes to thinness as part of its alliance with Merck (9/30) |
|
||||
Diversa Corp. (DVSA) |
Givaudan Flavors Corp. |
ND |
Milestone payment |
Diversa received a payment for the development of a biocatalyst that significantly improves the efficient production of a natural flavor ingredient (9/3) |
|
||||
Epimmune Inc. (EPMN) |
Anosys Inc. |
ND |
Milestone payment |
Epimmune received the payment after Anosys filed an investigational new drug application for a product that uses Epimmune technology under a license granted August 2001 (9/9) |
|
||||
Genmab A/S (Denmark; CSE:GEN) |
Amgen Inc. (AMGN) |
$0.5 |
Milestone payment |
Genmab achieved the payment for delivering an antibody that targets the interleukin-15 receptor (9/16) |
|
||||
Vicuron Pharmaceuticals Inc. (MICU) |
Novartis Pharma AG (Switzerland) |
ND |
Milestone payment |
Vicuron received the payment for achieving a milestone in its ongoing research collaboration focused on the development of peptide deformylase inhibitor antibiotics (9/4) |
|
||||
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed. | ||||
CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange. |